Maintenance monotherapy with gemcitabine after standard platinum‐based chemotherapy in patients with advanced urothelial cancer
Authors:
- 28 February 2015
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 22 (5) , 490-494
Abstract
Objectives: To investigate the outcomes of gemcitabine maintenance monotherapy treatment for metastatic urothelial cancer.Methods: Gemcitabine maintenance monotherapy was used for metastatic urothelial cancer patients after standard platinum‐based chemotherapy. A standard dose of 1000 mg/m2/month was given. If patients suffered adverse events or a noticeably compromised quality of life, treatment intervals were extended and doses lowered. Patients with metastatic urothelial cancer receiving only best supportive care after standard chemotherapy served as the retrospective control group.Results: A total of 33 patients were included in the study group as well as in the control group. Maintenance therapy was administered a median of nine times (range 2–49 times) with a median dose of 984.2 mg (range 500–1400 mg) per time. An adverse event of the Common Terminology Criteria of Adverse Events grade 3 or greater was observed in 10 (30.3%) patients, while nine patients (27.3%) experienced hematotoxicity. After standard chemotherapy pretreatment, disease‐specific survival in the maintenance therapy group was an average of 15.0 months, significantly more favorable (P < 0.001) than that of the control group (4.0 months). On multivariate analysis, efficacy of prior chemotherapy (P = 0.018), visceral metastasis (P = 0.007) and gemcitabine maintenance therapy (P < 0.001) were statistically significant prognostic parameters of disease‐specific survival.Conclusion: The present study findings suggest that gemcitabine maintenance monotherapy in metastatic urothelial cancer might not only be useful as a palliative treatment, but it could also have a certain level of therapeutic effectiveness.Keywords
This publication has 21 references indexed in Scilit:
- Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapyCancer, 2013
- Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: A retrospective studyInternational Journal of Urology, 2011
- Gemcitabine chemotherapy for the treatment of metastatic bladder carcinomaBJU International, 2011
- Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU GuidelinesEuropean Urology, 2011
- Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy: A Japanese ExperienceJapanese Journal of Clinical Oncology, 2007
- Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trialLung Cancer, 2006
- Maintenance chemotherapy in non-small cell lung cancerAnnals of Oncology, 2006
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)?Cancer, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- UPDATE ON CHEMOTHERAPY FOR ADVANCED BLADDER CANCERJournal of Urology, 2005